GlassScriptPhysician profile
Ian D Weir
NPI 1548368293
$3,201.56
in general payments reported to CMS, 2019-2025
22 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $63.31 · 2021: $93.21 · 2022: $811 · 2023: $95.25 · 2024: $405 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Consulting Fee: $350 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.43 |
| Consulting Fee | $350.00 |
| Education | $169.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $540.96 | 2019-2025 | Fasenra, Tezspire |
| Olympus Corporation of The Americas | $464.92 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $317.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.07 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $229.61 | 2025 | Lumryz |
| Harmony Biosciences LLC | $195.02 | 2025 | |
| Genzyme Corporation | $190.22 | 2023-2025 | |
| Amgen INC. | $162.30 | 2019-2022 | |
| Inari Medical, INC. | $144.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $137.51 | 2019-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $88.99 | 2024 | |
| Verona Pharma, INC. | $71.70 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $65.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.98 | 2019-2024 | Keytruda |
| Insmed, INC. | $57.63 | 2025 | Arikayce, Brinsupri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $44.27 | 2023 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $37.16 | 2019 | |
| Glaxosmithkline, LLC. | $28.32 | 2025 | Nucala |
| Grifols USA, LLC | $27.13 | 2025 | Prolastin-C Liquid |
| Celgene Corporation | $20.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.47 | 2019 | |
| Electromed, INC. | $16.15 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.